GlassScriptPhysician profile
Parvin Azizi
NPI 1215192083
$503.31
in general payments reported to CMS, 2019-2025
11 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $186 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $254.16 | 2024-2025 | Fintepla, Briviact |
| Otter Pharmaceuticals, LLC | $33.39 | 2025 | Sympazan |
| Abbvie INC. | $32.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $32.97 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $32.64 | 2024 | Ajovy |
| Tris Pharma INC | $32.63 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Corium, LLC | $18.98 | 2024 | Azstarys |
| Soleno Therapeutics, INC. | $17.52 | 2025 | Vykat Xr |
| Collegium Pharmaceutical, INC. | $16.81 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $16.38 | 2025 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $14.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvin Azizi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.